Pharmaceutical formulations

A tablet comprising:

• (a) from 3 mg to 60 mg of bexagliflozin;
• (b) from 50 mg to 75 mg of polyethylene oxide having an average molecular weight of 900,000 g/mol;
• (c) from 100 mg to 140 mg of glyceryl dibehenate;
• (d) from 40 mg to 50 mg of lactose;
• (e) from 40 mg to 45 mg of poloxamer 188;
• (f) from 60 mg to 80 mg of microcrystalline cellulose;
• (g) from 4 mg to 5 mg of colloidal silicon dioxide;
• and
• (h) from 6 mg to 9 mg of magnesium stearate,
• wherein the tablet provides a maximum bexagliflozin plasma concentration in a fasted human subject between 80-150 ng/mL.